Skip to content

Oral Manifestation in Patients With SARS-CoV2 Infection.

Oral Manifestation in Patients With SARS-CoV2 Infection.

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04821986
Enrollment
583
Registered
2021-03-30
Start date
2021-04-01
Completion date
2021-10-15
Last updated
2021-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

SARS-CoV Infection

Keywords

oral Manifestation, SARS-CoV2, prevelance

Brief summary

The oral cavity is particularly susceptible to viral infection with several viruses such as herpes simplex virus, cytomegalovirus and Zika virus because of its structures, especially salivary glands and soft tissues Moreover, oral mucosa can be affected by secondary pathological process of a bacterial or fungal nature due to viral immunosuppression. The oral cavity could be considered a biological barometer of both viral infection and viral immunosuppression advancement .

Detailed description

The SARS-Cov2 virus was identified in china at the end of 2019 and spread worldwide causing a global pandemic. Current research showed that SARS-Cov2 virus invades human cells via the receptor angiotensin-converting enzyme 2 (ACE2) through scRNA-seq data analyses. The study identified the organs that are at risk and are vulnerable to SARS-CoV-2 infection. Therefore, cells with ACE2 receptor distribution may become host cells for the virus and cause inflammatory response in related organs and tissues, such as the tongue mucosa and salivary glands. These results suggest that oral mucosa could be a target of SARS-CoV-2 infection . Although many authors reported the presence of oral lesion associated with SARS-CoV2 infection, the prevalence of the oral manifestation and the range of oral manifestation are still unknown. Further studies are necessary to better understanding of the symptoms of the SARS-CoV2 virus in order to faster detection. A multidisciplinary team following the patients could be the key in treatment of the infection and faster recovery.

Interventions

None listed

Sponsors

Fayoum University
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* A diagnosis of SARS-CoV2 with PCR. * Age range from 18-60 years old

Exclusion criteria

* Pregnancy or contraceptive pills * Lactation * Any auto-immune disease that could affect the oral mucosa * On any neoplastic therapy. * Uncontrolled diabetes

Design outcomes

Primary

MeasureTime frameDescription
oral manifestationone weekdescribe the patient oral manifestation

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026